LifeStance Health Surpasses Q1 Revenue and EBITDA Estimates, Lifts Full-Year Outlook
Summary
LifeStance Health reported a strong first quarter, significantly exceeding analyst expectations for both revenue and adjusted EBITDA. Q1 revenue reached $403.5 million, well above the $387.4 million estimate, while adjusted EBITDA hit $51.1 million, surpassing the $42.4 million estimate. The company also reported a net income of $14.2 million and provided an optimistic full-year outlook, with revenue guidance of $1,640-$1,680 million and adjusted EBITDA guidance of $200-$220 million, both above current IBES estimates. This robust performance indicates strong operational momentum and continued profitability, building on the return to profitability reported in FY25. Traders will likely view this as a significant positive catalyst, potentially driving the stock higher, especially given its current proximity to its 52-week high. Investors will watch for continued execution against this raised guidance and further improvements in internal controls.
At the time of this announcement, LFST was trading at $7.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.74 to $8.09. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.